Healthcare is undergoing a revolution driven by the “digital exhaust” defined as the continuous stream of biometric data generated by over 340 wearable devices and 300,000 health-related apps. This wealth of information forces the pharmaceutical industry to integrate wellness, prevention, and continuous patient engagement into its core business model. This unexplored territory offers major benefits: personalized treatment, drastically improved medication adherence, and the ability to move from reactive to proactive disease management. Furthermore, this data provides deep insights into real-life patient behavior, patterns invisible in traditional clinical settings, allowing for the design of safer and more effective therapies.
Therefore, successfully leveraging this shift requires strategic collaboration between pharma (therapeutic expertise) and wearable manufacturers (data generation) to convert raw data into validated, regulatory-ready evidence. In this article, Alcimed explains the potential of digital exhaust in healthcare and how partnerships between pharmaceutical companies can help unlock this potential.
Healthcare is entering a new era characterized by the constant stream of information generated by wearables and connected devices. From smartphones that count steps to advanced smartwatches that measure heart rhythm, oxygen levels, sleep quality and even gait, these devices are generating what experts call “digital exhaust” defined as the continuous biometric data that is generated in the background through interaction with everyday life technology.
A health report from 20241IQVIA. (n.d.). Digital Health Trends 2024. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/digital-health-trends-2024 revealed that more than 300,000 health-related apps and over 340 wearable devices are now actively collecting patient data, indicating significant development in the wearables and digital health ecosystem. For the pharmaceutical industry, this wealth of information engages both new problematics and exciting possibilities. Instead of focusing only on treating diseases, pharma is now exploring how it can integrate wellness, prevention and patient engagement into its core business model. The pharma leaders of the future will be those who not only gain access to vast health datasets, but also translate them into better treatments and patient outcomes.
This “digital exhaust” is not only transforming patient care but also creating new opportunities for pharmaceutical companies to understand diseases, optimize therapies, and design more effective interventions.
Biometric data reveals patterns invisible in clinical condition (nocturnal glucose spikes, activity changes,..) that can steer product development and therapy optimization. These real-world insights create strategic advantages for pharma in designing treatments that reflect patients’ actual experiences. Looking ahead, the development of digital twins, i.e. virtual images of individual patients that combine clinical, demographic and biometric data, will help to test, refine and predict therapies in future, even before they are administered in real life.
Real-time insights enable customized treatments instead of generic protocols. Smart insulin pens linked to continuous glucose monitors, for example, have shown that skipping just two basal or four bolus doses in 14 days can reduce time-in-range (TIR), a key metric for glucose control, by more than 5%. Consistent use of these tools leads to better results as adherence to therapy is tracked and fine-tuned.2Danne, T. P., Joubert, M., Hartvig, N. V., Kaas, A., Knudsen, N. N., & Mader, J. K. (2024). Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care, 47(6), 995‑1003. https://doi.org/10.2337/dc23-2176
Wearables and remote monitoring tools are transforming how chronic and acute conditions are managed. Continuous tracking enables early detection of issues (atrial fibrillation, …) while digital ECG patches or smartwatches validate diagnostics faster and more reliably than traditional care. Besides, home-based monitoring reduce hospital readmissions and emergency visits, allowing timely interventions before conditions escalate. Together, these advances move care from reactive to proactive disease management and prevention.
The shift from periodic clinical assessments to continuous streaming of health indicators is also transforming the collection of patient’s information. Hence, patient’s digital exhaust provides objective, repeatable, and scalable measures, enabling therapies that are safer, more aligned with daily life, and ultimately more effective.
The existing and potential benefits of the biometric digital exhaust are clear, and that is why pharma companies are beginning to integrate these insights into their strategies. Both to improve patient care and to tap into a significant market. However, realizing these benefits on a large scale requires more than just the technology. Wearable companies generate extensive streams of continuous data, while pharmaceutical companies bring therapeutic expertise, clinical insights and global reach. At the intersection of these capabilities, strategic collaboration can transform raw biometric data into validated insights, regulatory-ready evidence and ultimately improved patient care.
Specific examples illustrate the power of these partnerships.
For the pharmaceutical industry, these technologies offer new insight into patient behaviour and physiology, allowing subtle changes and unmet needs to be identified much earlier than traditional clinic visits.
Furthermore, regulators are now recognizing the transformative potential of these technologies. The FDA explicitly acknowledges that digital health tools can capture data more frequently and continuously than traditional trial visits, providing deeper insights into the efficacy and safety of treatments. Initiatives such as the 21st Century Cures Act and the FDA’s Real-World Evidence Program highlight the increasing integration of continuous digital data into drug development and regulatory decision-making.6Iulita MF, Streel E, Harrison J. Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change. Alzheimers Dement (N Y). 2025 Jun 2;11(2):e70114. doi: 10.1002/trc2.70114. PMID: 40463636; PMCID: PMC12130567.
Together, these examples show how partnerships between wearables and pharmaceutical companies are actively redefining clinical trials, chronic disease management and preventive care. This shows how biometric digital exhaust is already shaping patient treatment management and will only grow in importance in the coming decades.
Discover our consulting services in the healthcare industry >
It is no longer enough to view wearable data as a technological novelty or a potential add-on to clinical research. The real value lies in how this continuous stream of biometric data can reshape therapies, disease management and patient engagement. By focusing on outcomes rather than isolated data points, healthcare can move from reactive care to a model that is predictive, personalized and preventive.
Activating this transition requires more than technical skills. It also requires trust, collaboration, and the willingness of pharmaceutical companies, wearable manufacturers, regulators, and providers to work together toward common goals. The task is challenging and demanding. Yet the potential benefits, including safer medicines, more efficient trials, personalized treatments, and healthier lives, justify the effort. For those who succeed, the biometric digital exhaust will not only improve care today, but also help shape the future of medicine.
The biometric digital exhaust calls for a transition from episodic clinical visits to continuous monitoring, shifting care toward a predictive, personalized, and preventive model. Strategic partnerships are already demonstrating their power in improving medication adherence and clinical outcomes.
Alcimed can support you in effectively navigating this complex data landscape and reshaping therapies, securing a competitive advantage in the future of medicine. Don’t hesitate to contact our team!
About the author,
François, Consultant in Alcimed’s Healthcare team in France
Data - AI
Use case n°1: treatment adherence enhancement through treatment reminders and medication management In the complex world of healthcare, adhering to treatment plans and medication schedules is ...
Data - AI
Reason n°1: optimizing the agenda and operations allows a quicker and more efficient organization Data analysis and artificial intelligence can empower sales reps with valuable information, ...
Healthcare
Challenge n°1: Develop knowledge about rare diseases Research into rare diseases is hampered by a lack of knowledge of the biological mechanisms involved and a limited understanding of how these ...